Business Wire

  1. Future Drug Pipelines And Prospects Revealed For RNAi Therapeutics 10/20/2008
    Research and Markets has announced the addition of the "The Future of RNAi Therapeutics: Drug Pipelines and Prospects" report to their offering.
  2. Teva Announces FDA Approval And Commercial Launch Of Fentanyl Transdermal System 10/20/2008
    Teva Pharmaceutical Industries Ltd.,announced today that the U.S. Food and Drug Administration has granted approval for the Company’s Abbreviated New Drug Application (ANDA) for Fentanyl Transdermal System, 25 mcg/hour, 50 mcg/hour, 75 mcg/hour and 100 mcg/hour, the AB-rated generic equivalent of Ortho McNeil’s chronic pain treatment Duragesic.
  3. TB Alliance Enters Into Collaboration With Sanofi-Aventis To Fight Tuberculosis 10/14/2008
    The Global Alliance for TB Drug Development (TB Alliance) and sanofi-aventis announced today that they have entered into a collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis (TB).
  4. PFD Releases New QbD Tools 10/14/2008
    Performance Fluid Dynamics (PFD) Limited, the leading provider of unit operation modeling software to the pharmaceutical industry, today announced the release of DynoChem 2008, with extensive new support for the Quality by Design (QbD) initiative.
  5. Alcon Announces Two Agreements Designed To Expand Its Future Drug Portfolio 10/14/2008
    Alcon, Inc. announced today that it has executed a new agreement and broadened an existing agreement with two different companies to expand its products under development. Alcon entered into a licensing agreement with GlaxoSmithKline (“GSK”) for global ophthalmic rights to cilomilast, a phosphodiesterase IV inhibitor.
  6. Microfluidics Introduces New Services Designed To Enhance Customer Success 10/13/2008
    Microfluidics, announces the availability of several new services designed to enhance customer success and assist in customer innovation.
  7. Akorn, Inc. Enters Into A Commercial Manufacturing Supply Agreement 10/13/2008
    Akorn, Inc., a specialty pharmaceutical company and an undisclosed ophthalmic company have entered into a five year supply agreement for an ophthalmic product. Akorn is the ANDA holder of the product.
  8. Invitrogen Redesigns GIBCO® Bottle To Improve Form And Function 10/13/2008
    Invitrogen Corporation, a provider of essential life science technologies for research, production and diagnostics, announced the global launch of its updated GIBCO cell culture media bottles.
  9. Medidata Solutions Announces New Capabilities To Streamline Clinical Trial Start-Up And FDA Submissions 10/9/2008
    Medidata Solutions, today announced enhancements to Medidata Rave, its unified electronic data capture (EDC) and clinical data management (CDM) platform, which will enable sponsors and CROs to quickly and efficiently build studies, streamline start-up times and submissions, and enhance trial quality.
  10. BioVigilant Submits Drug Master Files To U.S. FDA, Accelerating Regulatory Approval Process For Instantaneous Microbial Detection Equipment Use 10/9/2008
    BioVigilant Systems, Inc., today announced that the Company has submitted two Type V Drug Master Files (DMFs) to the U.S. Food and Drug Administration (FDA) for its IMD-A product line, a family of products used for rapid environmental air monitoring in pharmaceutical environments.